abemaciclib治疗乳腺癌患者与医师沟通情况在线调查

Q4 Medicine Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-12-01
Chihiro Iseki, Naoko Toriguchi, Yoshinori Tanizawa, Nobuyuki Sekine, Seiko Mizuno, Satoshi Osaga, Hiroko Bando
{"title":"abemaciclib治疗乳腺癌患者与医师沟通情况在线调查","authors":"Chihiro Iseki, Naoko Toriguchi, Yoshinori Tanizawa, Nobuyuki Sekine, Seiko Mizuno, Satoshi Osaga, Hiroko Bando","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To describe the actual communication of patients with breast cancer on oral abemaciclib treatment and the motivating factors to continue treatment.</p><p><strong>Methods: </strong>An online survey was conducted in July and August 2023 across Japan among patients aged ≥18 years who were undergoing or had prior experience with abemaciclib treatment and physicians who had prescribed abemaciclib during the past year.</p><p><strong>Results: </strong>Responses from 80 patients and 78 physicians were obtained. The main explanations patients received from their physicians before/after starting treatment were related to side effects (90%)and effectiveness(88%). Regarding management of side effects, both patients(66%)and physicians(54%) responded that\"easy-to-understand explanations on how to deal with side effects\"is necessary. The proportion of patients who received an explanation from their physician on how to deal with side effects was relatively low. A notable challenge experienced by patients when they had side effects was \"I don't know how severe my symptoms should be before contacting or visiting the hospital\".</p><p><strong>Conclusions: </strong>The results of this survey suggest that specific, easy-to-understand information from healthcare professionals on adverse events and how to deal with them could help patients more appropriately self-manage abemaciclib treatment.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 12","pages":"1227-1237"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Online Survey about Communication between Abemaciclib-Treated Patients with Breast Cancer and Physicians].\",\"authors\":\"Chihiro Iseki, Naoko Toriguchi, Yoshinori Tanizawa, Nobuyuki Sekine, Seiko Mizuno, Satoshi Osaga, Hiroko Bando\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To describe the actual communication of patients with breast cancer on oral abemaciclib treatment and the motivating factors to continue treatment.</p><p><strong>Methods: </strong>An online survey was conducted in July and August 2023 across Japan among patients aged ≥18 years who were undergoing or had prior experience with abemaciclib treatment and physicians who had prescribed abemaciclib during the past year.</p><p><strong>Results: </strong>Responses from 80 patients and 78 physicians were obtained. The main explanations patients received from their physicians before/after starting treatment were related to side effects (90%)and effectiveness(88%). Regarding management of side effects, both patients(66%)and physicians(54%) responded that\\\"easy-to-understand explanations on how to deal with side effects\\\"is necessary. The proportion of patients who received an explanation from their physician on how to deal with side effects was relatively low. A notable challenge experienced by patients when they had side effects was \\\"I don't know how severe my symptoms should be before contacting or visiting the hospital\\\".</p><p><strong>Conclusions: </strong>The results of this survey suggest that specific, easy-to-understand information from healthcare professionals on adverse events and how to deal with them could help patients more appropriately self-manage abemaciclib treatment.</p>\",\"PeriodicalId\":35588,\"journal\":{\"name\":\"Japanese Journal of Cancer and Chemotherapy\",\"volume\":\"51 12\",\"pages\":\"1227-1237\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Cancer and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:了解乳腺癌患者口服阿贝马昔单抗治疗的实际沟通情况及继续治疗的激励因素。方法:于2023年7月和8月在日本进行一项在线调查,调查对象为年龄≥18岁、正在接受或曾接受过阿贝马昔lib治疗的患者以及在过去一年中开过阿贝马昔lib处方的医生。结果:共获得80名患者和78名医生的反馈。患者在开始治疗前后从医生处得到的主要解释是副作用(90%)和疗效(88%)。对于副作用的处理,患者(66%)和医生(54%)都认为有必要“简单易懂地解释如何处理副作用”。从医生那里得到如何处理副作用的解释的患者比例相对较低。患者在出现副作用时遇到的一个显著挑战是“在联系或访问医院之前,我不知道我的症状应该有多严重”。结论:本调查结果表明,医疗保健专业人员提供的关于不良事件及其处理方法的具体、易于理解的信息可以帮助患者更适当地自我管理阿贝马昔单抗治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Online Survey about Communication between Abemaciclib-Treated Patients with Breast Cancer and Physicians].

Objective: To describe the actual communication of patients with breast cancer on oral abemaciclib treatment and the motivating factors to continue treatment.

Methods: An online survey was conducted in July and August 2023 across Japan among patients aged ≥18 years who were undergoing or had prior experience with abemaciclib treatment and physicians who had prescribed abemaciclib during the past year.

Results: Responses from 80 patients and 78 physicians were obtained. The main explanations patients received from their physicians before/after starting treatment were related to side effects (90%)and effectiveness(88%). Regarding management of side effects, both patients(66%)and physicians(54%) responded that"easy-to-understand explanations on how to deal with side effects"is necessary. The proportion of patients who received an explanation from their physician on how to deal with side effects was relatively low. A notable challenge experienced by patients when they had side effects was "I don't know how severe my symptoms should be before contacting or visiting the hospital".

Conclusions: The results of this survey suggest that specific, easy-to-understand information from healthcare professionals on adverse events and how to deal with them could help patients more appropriately self-manage abemaciclib treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
337
期刊最新文献
[Online Survey about Communication between Abemaciclib-Treated Patients with Breast Cancer and Physicians]. [Survey on the Size of Oral Anticancer Drugs]. [Ⅰ. Personalized Perioperative Therapy in Luminal Breast Cancer]. [Ⅱ. Recurrence Score in Patients with BRCA1/2 Mutation from the OlympiA and TAILORx Trial Results]. [Ⅲ. MONARCH-E and Oncotype DX].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1